Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab

NCT04381494 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04381494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04381494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Terminated
Start date
April 27, 2020
Completion date
January 27, 2022
Enrollment
40 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable stage iii nsclc